Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Bukowski

Pediatric Urology Raleigh, NC Medical Doctor

NPI 1104843556 CMS profile 185612

3821 Ed Dr, Raleigh, NC 27612

Open in the dashboard

General payments

$2,086

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,879 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Timothy Bukowski of Raleigh, NC is reported in the CMS Open Payments database as having received $2,086 across 44 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,879 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 81st percentile of Pediatric Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107 1
2024 General $166 3
2023 General $195 4
2022 General $1,002 3
2021 General $204 13
2020 General $213 13
2019 General $200 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Bukowski
  • Pediatric Urology median
  • Middle half of Pediatric Urology
  • National median

In program year 2025, general payments to Timothy Bukowski were reported at $107. Among 246 Pediatric Urology profiles paid that year, the median was $129 and the middle half received between $42 and $322.

Show as a table
Year Timothy Bukowski Pediatric Urology median Middle half National median
2019 $200 $126 $41–$305 $163
2020 $213 $92 $29–$249 $114
2021 $204 $122 $34–$269 $132
2022 $1,002 $149 $52–$330 $149
2023 $195 $128 $48–$288 $160
2024 $166 $142 $55–$375 $164
2025 $107 $129 $42–$322 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Palette Life Sciences, Inc. $1,014 4 payments
  2. Dendreon Pharmaceuticals LLC $194 12 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $140 2 payments
  4. Urogen Pharma, Inc. $122 1 payment
  5. Blue Earth Diagnostics Limited $120 6 payments
  6. Astellas Pharma US Inc $113 1 payment
  7. Calyxo, Inc. $107 1 payment
  8. Allergan Inc. $43 3 payments
  9. Acerus Pharmaceuticals Corporation $39 3 payments
  10. ConvaTec Inc. $37 1 payment
  11. Other $156 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,216 43 payments
  2. Consulting Fee $870 1 payment
Products named General payments · program years 2019–2025
  1. DEFLUX $891 2 payments
  2. PROVENGE $194 12 payments
  3. Nubeqa $140 2 payments
  4. JELMYTO $122 1 payment
  5. Axumin $120 6 payments
  6. CVAC ASPIRATION SYSTEM $107 1 payment
  7. BOTOX Hyperhydrosis $43 3 payments
  8. Natesto $39 3 payments
  9. GENTLECATH $37 1 payment
  10. BOTOX Botox Therapeutic $36 2 payments
  11. Other $112 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Urology: 1,053

Drug cost

$25

Median for Urology: $101,464

Branded share of claims

100%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JELMYTO
  • UROGEN PHARMA, INC. $122
$122 — —
BOTOX
  • AbbVie, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Urology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record